Skip to main content
HR 1862 112th Congress House Health Advisory bodies Department of Health and Human Services Drug safety, medical device, and laboratory regulation Executive agency funding and structure Genetics Health programs administration and funding Health technology, devices, supplies Medical research Product development and innovation Research administration and funding Research and development

Regenerative Medicine Promotion Act of 2011

Introduced: May 12, 2011 See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
May 13, 2011
Referred to the Subcommittee on Health.
May 12, 2011
Referred to the House Committee on Energy and Commerce.
May 12, 2011
Introduced in House
 Plain-English summary Congressional Research Service

Regenerative Medicine Promotion Act of 2011 - Requires the Comptroller General to submit to Congress a report identifying all ongoing federal programs and activities regarding regenerative medicine.

Directs the Secretary of Health and Human Services (HHS) to establish a Regenerative Medicine Coordinating Council in the Office of the Secretary, the duties of which shall include: (1) preparing a national strategy to support research into regenerative medicine and the development of drugs, biological products, medical devices, and biomaterials for use in regenerative medicine; (2) identifying sources of funding for research into regenerative medicine and areas where such funding is inadequate; and (3) making recommendations regarding federal policies to support development and marketing of regenerative medicine products.

Authorizes the Secretary, acting through the Director of the National Institutes of Health (NIH), to make grants for: (1) basic or preclinical research into regenerative medicine; (2) research and development of drugs, biological products, medical devices, and biomaterials for use in regenerative medicine; and (3) the making of an investigational new drug application or an investigational device exemption application within four years of receiving such grant.

Amends the Public Health Service Act to authorize the Director of NIH to award grants, contracts, or cooperative agreements to accelerate the development of high need cures through the development of medical products and behavioral therapies for use in regenerative medicine.

Authorizes the Secretary, acting through the Commissioner of Food and Drugs, to: (1) conduct, support, or collaborate in regulatory research to assist the Food and Drug Administration (FDA) in performing its functions with respect to regenerative medicine; or (2) make grants to fund regulatory research for such purpose.

What's happening now May 13, 2011

Referred to the Subcommittee on Health.

 Committees of jurisdiction 2
 Cosponsors 4
All 4 Democratic 4